Chengdu Olymvax Biopharmaceuticals Inc. Class ASSE: 688319

Announcement on Voluntary Disclosure of Initiation of Phase I Clinical Trial for Trivalent and Tetravalent Influenza Vaccine (Split Virus, MDCK Cells) and Completion of First Subject Enrollment

· Issued by Chengdu Olymvax Biopharmaceuticals Inc. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Initiation of Phase I Clinical Trial for Trivalent and Tetravalent Influenza Vaccine (Split Virus, MDCK Cells) and Completion of First Subject Enrollment

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis